MICHAEL SALAMATBAD: Open Payments
NPI 1316104086 · GREAT NECK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$380 in 13 payments from 8 companies in 2025. Trend: 2023 $67 · 2024 $327 · 2025 $380
Food & beverage: $380
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $125 |
| Braeburn Inc. | 2 | $54 |
| PFIZER INC. | 3 | $54 |
| Lilly USA, LLC | 2 | $46 |
| Amgen Inc. | 2 | $37 |
| Dexcom, Inc. | 1 | $30 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $15 |
Products named: JARDIANCE, BRIXADI, MOUNJARO, ELIQUIS, Dexcom G6 Transmitter, OTEZLA, NUCALA, REPATHA.
Industry payments across NY — which companies pay providers there.
